NKG2A & CD94

NKG2A & CD94

NKG2A & CD94 Overview

Molecule Name
NK cell lectin-like receptor subfamily C member 1
Synonyms
NKG2A & CD94
Drug Development Progress
Drugs in Clinical Trials6
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
Background
CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

NKG2A & CD94 Product List

Species
  • Human(5)
  • Mouse(3)
  • Cynomolgus(2)
Tag
  • Fc Tag & Avi Tag(3)
  • His Tag(3)
  • Fc Tag(2)
  • His Tag & Avi Tag(1)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(10)
Conjugate
  • Unconjugated(6)
  • Biotin-labeled(4)
Grade
  • RUO(10)
Low Endotoxin
  • Yes(2)
  • No(8)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
NKG2A & CD94
HOTAvitag
NC4-M82F5
Biotinylated Mouse NKG2A&CD94 Protein, Fc,Avitag™
Mouse
HEK293
SDS-PAGE

$360.00

25ug
NKG2A & CD94
Human NKG2A&CD94 Protein, His Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISA

$395.00

100ug
NKG2A & CD94
Human NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$395.00

100ug
NKG2A & CD94
HOTAvitag
NC4-H82E4
Biotinylated Human NKG2A&CD94 Protein, His,Avitag™
Human
HEK293
SDS-PAGE
ELISA

$415.00

25ug
NKG2A & CD94
Cynomolgus NKG2A&CD94 Protein, His Tag
Cynomolgus
HEK293
SDS-PAGE
ELISA

$395.00

100ug
NKG2A & CD94
Avitag
NC4-C82F7
Biotinylated Cynomolgus NKG2A&CD94 Protein, Fc,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
NKG2A & CD94
Human NKG2A&CD94 Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$470.00

100ug
NKG2A & CD94
Avitag
NC4-H82F5
Biotinylated Human NKG2A&CD94 Protein, Fc,Avitag™
Human
HEK293
SDS-PAGE
ELISA

$360.00

25ug
NKG2A & CD94
Mouse NKG2A&CD94 Protein, Fc Tag
Mouse
HEK293
SDS-PAGE

$395.00

100ug
NKG2A & CD94
Mouse NKG2A&CD94 Protein, His Tag
Mouse
HEK293
SDS-PAGE

$395.00

100ug
You Have Viewed 1-10 Of 10 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
MonalizumabNNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201Phase 3 ClinicalNovo Nordisk A/S
Arthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
BMS-986315BMS-986315Phase 2 ClinicalBristol-Myers Squibb Company
Carcinoma, Non-Small-Cell Lung; Solid tumours
Details
S-095029S-095029Phase 2 ClinicalInstitut De Recherches Internationales Servier
Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms
Details
HY000102HY-0102; HY-000102Phase 2 ClinicalShanghai HyaMab Biotech Co Ltd
Pancreatic Neoplasms; Solid tumours
Details
XB-628XB628Phase 1 ClinicalExelixis Inc
Neoplasms; Solid tumours
Details
BRY-805BRY805; BRY-805Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd
Solid tumours
Details
Customer Reviews